Clinical trials: Alzheimer Disease, At Risk
Alzheimer's Disease, Mild Cognitive Impairment
Cognition Platform Study in Participants at Risk for Alzheimer's Disease (AD) (MK-0000-413)
The main purpose of this study is to assess the ability of a repeated high-frequency site-based computerized cognitive assessment to evaluate the potential treatment effects of donepezil (MK-0000) compared with placebo among…
- Trial name
- NCT04730635
- Testing
- Donepezil
- Where
- 10 sites in United States, Australia
- Volunteers
- 44 people
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer's Disease, Hypertension
Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's
Angiotensin converting enzyme inhibitors (ACE-I) are a group of blood pressure-lowering medicines. Some studies suggest that ACE-I, such as ramipril, may help prevent Alzheimer's disease (AD).
- Trial name
- SEAIRA (NCT00980785)
- Testing
- Ramipril
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Cognitive Aging, Alzheimer Disease, Protection Against
The Revitalize Study in Older Adults at Risk for Alzheimer's Disease
The goal of this multi-site double blinded randomized sham-controlled Phase II clinical trial is to test a novel, relatively low cost, low risk, and potentially high impact therapeutic intervention in older adults who are at…
- Trial name
- NCT04018092
- Testing
- Active NIR-PBM
- Where
- 2 sites in United States
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- University of Florida
Alzheimer Disease, At Risk, Alzheimer Disease, Protection Against
The STEP 4Life Trial
The objective of this study is to test the feasibility of using behavioral economic interventions (gamification with social incentives) targeting daily step counts to prevent or delay the development of Alzheimer's Disease and…
- Conditions
- Alzheimer Disease, At Risk, Alzheimer Disease, Protection Against, Dementia
- Trial name
- NCT05069155
- Testing
- Gamification
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- University of Pennsylvania
Alzheimers Disease
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
The purpose of this study is to determine the effects of CNP520 on cognition, global clinical status, and underlying AD pathology, as well as the safety of CNP520, in people at risk for the onset of clinical symptoms of AD based…
- Trial name
- GS2 (NCT03131453)
- Testing
- CNP520 50mg, CNP520 15mg
- Where
- 194 sites in United States, Argentina and 23 more
- Volunteers
- 1,145 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease
Statin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for Alzheimer's Disease
The purpose of the research is to see how simvastatin affects a substance in the body called beta-amyloid. Beta-amyloid is found in the brain and in the liquid around the brain and spinal cord.
- Trial name
- SHARP (NCT00939822)
- Testing
- Simvastatin
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Genetic Risk for Alzheimer's Disease
Effects of Donepezil HCL on Task-Activated fMRI Brain Activation in Healthy Older Adults at Genetic Risk for Alzheimer's Disease
This study examines the sensitivity of functional MRI to detect brain changes caused by donepezil HCL (a cholinesterase inhibitor) in healthy older adults at genetic risk for Alzheimer's Disease.
- Trial name
- NCT02087865
- Testing
- donepezil HCL
- Where
- United States
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Alzheimers Disease, Dementia
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation
The purpose of this study is to assess the safety, tolerability, biomarker, cognitive and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with…
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Trial name
- DIAN-TU (NCT06424236)
- Testing
- Gantenerumab
- Where
- 17 sites in United States, Australia and 4 more
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Alzheimer's Disease
Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease
Recent data show that marked cell damage precedes the clinical manifestation of Alzheimer's disease (AD). Hence, targeting populations at risk with pharmacological interventions is a possible strategy to lessen the burden of the…
- Trial name
- NCT00933608
- Testing
- memantine
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Aging
Safety and Feasibility of Dasatinib and Quercetin in Adults at Risk for Alzheimer's Disease
The purpose of this pilot study is to demonstrate the safety and feasibility of administering intermittent doses of Dasatinib and Quercetin (D+Q) in older adults at risk of Alzheimer's disease (AD).
- Trial name
- STAMINA (NCT05422885)
- Testing
- Dasatinib, Quercetin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Lewis Lipsitz
Physical Inactivity
Intergenerational Behavioral Intervention to Enhance Physical Activity in Older Adults at Risk for Alzheimer's Disease
This is a four-week pilot randomized controlled trial of a behavioral intervention in older adults at risk for Alzheimer's disease. Older participants are a subgroup from the PREVENT-AD longitudinal cohort.
- Trial name
- HABS (NCT06038643)
- Testing
- Motivational behavioural intervention and daily activities monitoring, Active Control
- Where
- Canada
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Douglas Mental Health University Institute
Asymptomatic Amyloid-positive
An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia
The purpose of this study is to evaluate whether treatment with atabecestat slows cognitive decline compared with placebo treatment, as measured by a composite cognitive measure, the Preclinical Alzheimer Cognitive Composite…
- Trial name
- EARLY (NCT02569398)
- Testing
- Atabecestat, 5 mg, Atabecestat, 25 mg
- Where
- 128 sites in United States, Australia and 11 more
- Volunteers
- 557 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Alzheimer's Disease, Aging
aeRobic Exercise and Cognitive Health
The purpose of the aeRobic Exercise and Cognitive Health (REACH) study is to understand how an aerobic exercise intervention might help promote brain health and cognition, thereby delaying the onset of clinical symptoms of…
- Trial name
- REACH (NCT02384993)
- Testing
- Enhanced Physical Activity
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Alzheimers Disease
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
The purpose of this study was to test whether two investigational drugs called CAD106 and CNP520, administered separately, could slow down the onset and progression of clinical symptoms associated with Alzheimer's disease (AD) in…
- Trial name
- GS1 (NCT02565511)
- Testing
- CAD106 Immunotherapy, CNP520, Alum
- Where
- 129 sites in United States, Australia and 8 more
- Volunteers
- 480 people
- Sponsor
- Novartis Pharmaceuticals
Cognition Disorders
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid (protein that forms plaques in the brains of people with Alzheimer…
- Trial name
- A4 (NCT02008357)
- Testing
- Solanezumab
- Where
- 68 sites in United States, Australia and 2 more
- Volunteers
- 1,169 people
- Sponsor
- Eli Lilly and Company
Alzheimers Disease
A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD)
A study to evaluate the efficacy and safety of gantenerumab in amyloid-positive, cognitively unimpaired participants at risk for or at the earliest stages of AD.
- Trial name
- SKYLINE (NCT05256134)
- Testing
- Gantenerumab
- Where
- 63 sites in United States, Argentina and 8 more
- Volunteers
- 25 people
- Sponsor
- Hoffmann-La Roche
Alzheimer Disease, Dementia
Movement Intervention for Memory Enhancement
Dancing is a complex sensorimotor rhythmic activity that integrates cognitive, physical, and social components and is applicable to seniors with various fitness levels.
- Conditions
- Alzheimer Disease, Dementia, Cognitive Decline, Cognitive Impairment
- Trial name
- MIME (NCT03475316)
- Testing
- Social Dancing, Treadmill Walking
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Albert Einstein College of Medicine
Adherence, Treatment, Retention
KNA Proof-of-Concept
The intervention program proof-of-concept was assessed as a single-arm, within-subjects clinical study with a target enrollment of 10 participants with possible or probable amnestic MCI.
- Conditions
- Adherence, Treatment, Retention, Cognitive Impairment, Mild
- Trial name
- NCT04968041
- Testing
- Motivational Interviewing-Cognitive Behavioral Therapy Ketogenic Nutrition Adherence Program
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Florida State University
Alzheimers Disease, Dementia
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.
The purpose of this study is to assess the safety, tolerability, biomarker and cognitive efficacy of investigational products in subjects who are known to have an Alzheimer's disease-causing mutation by determining if treatment…
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Trial name
- DIAN-TU (NCT04623242)
- Testing
- Gantenerumab, Solanezumab
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine